Matthew leads Sitryx’s medicinal chemistry, CMC and intellectual property activities.
He has over 20 years’ experience in drug discovery and development, having formerly held positions as Head of Chemistry and Intellectual Property at TopiVert (London), Director of Drug Discovery at Oryzon (Barcelona) and Director of Medicinal Chemistry at Prosidion (Oxford). Matthew has successfully led research endeavours in multiple therapeutic areas, delivering compounds that have reached Phase 2 or further in oncology, immunology, metabolic disease, neurology and ophthalmology. Several of these compounds have been purchased by major pharma companies.
Matthew obtained degrees from the University of Glasgow (BSc), Columbia University (MA) and the University of Birmingham (PhD) prior to postdoctoral studies at UCLA with Nobel prize winner Sir Fraser Stoddart. He is a Chartered Chemist, a Fellow of The Royal Society of Chemistry, an author of more than 40 peer-reviewed publications and an inventor on over 75 patent applications.